The value of vaccination: a global perspective.

[1]  Reuben Samuel,et al.  Herd immunity and herd effect: new insights and definitions , 2004, European Journal of Epidemiology.

[2]  J. Ehreth.  The global value of vaccination. , 2003, Vaccine.

[3]  Jeffrey R. Harris,et al.  Priorities among recommended clinical preventive services. , 2001, American journal of preventive medicine.

[4]  L. Barker,et al.  National, state and urban-area vaccination-coverage levels among children aged 19-35 months, United States, 1999. , 2001, American journal of preventive medicine.

[5]  R. Breiman.  Vaccines as tools for advancing more than public health: perspectives of a former director of the National Vaccine Program office. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  M. Meltzer,et al.  Economic evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997. , 2000, Archives of pediatrics & adolescent medicine.

[7]  B. Hersh,et al.  Review of regional measles surveillance data in the Americas, 1996–99 , 2000, The Lancet.

[8]  H. Peltola.  Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. , 2000, Clinical microbiology reviews.

[9]  H. Hull,et al.  Eradication of poliomyelitis in countries affected by conflict. , 2000, Bulletin of the World Health Organization.

[10]  M. Miller,et al.  Policy analysis of the use of hepatitis B, Haemophilus influenzae type b-, Streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedules. , 2000, Health economics.

[11]  A. Shearley,et al.  The societal value of vaccination in developing countries. , 1999, Vaccine.

[12]  V. Goulet,et al.  INFECTIONS INVASIVES A HAEMOPHILUS INFLUENZAE, LISTERIA MONOCYTOGENES, MENINGOCOQUE, PNEUMOCOQUE, STREPTOCOQUES GROUPE A ET GROUPE B, EN FRANCE EN 1997 EVOLUTION 1991-1997 , 1999 .

[13]  E. Miller,et al.  Impact of anti-vaccine movements on pertussis control: the untold story , 1998, The Lancet.

[14]  R. Aylward,et al.  Integrated disease control initiatives: polio eradication and neonatal tetanus elimination in Egypt. , 1997, The Journal of infectious diseases.

[15]  P. van Damme,et al.  Costs and benefits of routine varicella vaccination in German children. , 1996, The Journal of infectious diseases.

[16]  V. Dietz,et al.  Performance and potency of tetanus toxoid: implications for eliminating neonatal tetanus. , 1996, Bulletin of the World Health Organization.

[17]  Tammy O. Tengs,et al.  Five-hundred life-saving interventions and their cost-effectiveness. , 1995, Risk analysis : an official publication of the Society for Risk Analysis.

[18]  D. Shepard.  Economic analysis of investment priorities for measles control. , 1994, The Journal of infectious diseases.

[19]  F. Stanley,et al.  The burden of Haemophilus influenzae type b disease in Australia ana an economic appraisal of the vaccine PRP‐OMP , 1994, The Medical journal of Australia.

[20]  E. Zell,et al.  Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. , 1993, JAMA.

[21]  R. Martorell,et al.  Effectiveness of vitamin A supplementation in the control of young child morbidity and mortality in developing countries. Revised ed. , 1993 .

[22]  D. Jamison,et al.  Disease Control Priorities in Developing Countries , 1993 .

[23]  D. Henderson.  The eradication of smallpox. , 1976, Scientific American.